D. E. Shaw & Co., Inc. Biogen Inc. Call Options Transaction History

D. E. Shaw & Co., Inc.

$107 Billion
Q3 2024

Call Options

18 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$189.07 - $236.8 $1.29 Million - $1.61 Million	-6,800 Reduced 73.91%	2,400 $465,000
Q2 2024 Aug 14, 2024	SELL	$190.52 - $236.72 $514,404 - $639,144	-2,700 Reduced 22.69%	9,200 $2.13 Million
Q1 2024 May 15, 2024	BUY	$212.02 - $267.71 $2.52 Million - $3.19 Million	11,900 New	11,900 $2.57 Million
Q3 2022 Nov 14, 2022	SELL	$194.69 - $268.46 $1.95 Million - $2.68 Million	-10,000 Reduced 50.0%	10,000 $2.67 Million
Q2 2022 Aug 15, 2022	SELL	$187.54 - $223.02 $11.8 Million - $14.1 Million	-63,000 Reduced 75.9%	20,000 $4.08 Million
Q1 2022 May 16, 2022	BUY	$193.77 - $244.14 $14.1 Million - $17.8 Million	73,000 Added 730.0%	83,000 $17.5 Million
Q3 2020 Nov 16, 2020	SELL	$264.77 - $305.71 $10.6 Million - $12.2 Million	-40,000 Reduced 80.0%	10,000 $2.84 Million
Q2 2020 Aug 14, 2020	BUY	$258.66 - $342.55 $5.17 Million - $6.85 Million	20,000 Added 66.67%	50,000 $13.4 Million
Q1 2020 May 15, 2020	SELL	$268.85 - $341.04 $3.84 Million - $4.88 Million	-14,300 Reduced 32.28%	30,000 $9.49 Million
Q4 2019 Feb 14, 2020	SELL	$220.06 - $304.07 $8.8 Million - $12.2 Million	-40,000 Reduced 47.45%	44,300 $13.1 Million
Q2 2019 Aug 14, 2019	BUY	$219.29 - $241.72 $13.2 Million - $14.5 Million	60,000 Added 246.91%	84,300 $19.7 Million
Q1 2019 May 15, 2019	SELL	$216.71 - $338.96 $32.5 Million - $50.9 Million	-150,100 Reduced 86.07%	24,300 $5.74 Million
Q4 2018 Feb 14, 2019	BUY	$278.5 - $352.75 $13.9 Million - $17.6 Million	50,000 Added 40.19%	174,400 $52.5 Million
Q3 2018 Nov 14, 2018	SELL	$293.51 - $383.83 $26.1 Million - $34.2 Million	-89,000 Reduced 41.71%	124,400 $44 Million
Q2 2018 Aug 14, 2018	BUY	$257.52 - $306.91 $21.7 Million - $25.9 Million	84,400 Added 65.43%	213,400 $61.9 Million
Q1 2018 May 15, 2018	SELL	$260.13 - $367.91 $14.6 Million - $20.6 Million	-56,100 Reduced 30.31%	129,000 $35.3 Million
Q4 2017 Feb 14, 2018	BUY	$307.64 - $344.58 $16.4 Million - $18.4 Million	53,300 Added 40.44%	185,100 $59 Million
Q3 2017 Nov 14, 2017	BUY	$281.15 - $329.69 $37.1 Million - $43.5 Million	131,800	131,800 $41.3 Million

Others Institutions Holding BIIB

# of Institutions

1,037

Shares Held

126M

Call Options Held

1.13M

Put Options Held

1.43M

Vanguard Group Inc Valley Forge, PA

16.7M
Shares

$2.44 Billion
0.06% of portfolio
Primecap Management CO Pasadena, CA

16.3M
Shares

$2.39 Billion
2.37% of portfolio
Black Rock Inc. New York, NY

14.5M
Shares

$2.13 Billion
0.08% of portfolio
State Street Corp Boston, MA

7.34M
Shares

$1.08 Billion
0.06% of portfolio
Wellington Management Group LLP Boston, MA

5.13M
Shares

$752 Million
0.18% of portfolio

View Full List

About BIOGEN INC.

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $21.1B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

More about BIIB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account